146 related articles for article (PubMed ID: 11120940)
21. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects.
Hendrix CW; Wakeford J; Wire MB; Lou Y; Bigelow GE; Martinez E; Christopher J; Fuchs EJ; Snidow JW
Pharmacotherapy; 2004 Sep; 24(9):1110-21. PubMed ID: 15460171
[TBL] [Abstract][Full Text] [Related]
22. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
[TBL] [Abstract][Full Text] [Related]
23. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
Goodgame JC; Pottage JC; Jablonowski H; Hardy WD; Stein A; Fischl M; Morrow P; Feinberg J; Brothers CH; Vafidis I; Nacci P; Yeo J; Pedneault L
Antivir Ther; 2000 Sep; 5(3):215-25. PubMed ID: 11075942
[TBL] [Abstract][Full Text] [Related]
24. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
[TBL] [Abstract][Full Text] [Related]
25. Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers.
Darwish M; Hellriegel ET
Clin Ther; 2011 Jun; 33(6):746-53. PubMed ID: 21704239
[TBL] [Abstract][Full Text] [Related]
26. Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.
Eke AC; Wang J; Amin K; Shapiro DE; Stek A; Smith E; Chakhtoura N; Basar M; George K; Knapp KM; João EC; Rungruengthanakit K; Capparelli E; Burchett S; Mirochnick M; Best BM;
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015036
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.
Pérez-Elías MJ; Morellon ML; Ortega E; Hernández-Quero J; Rodríguez-Torres M; Clotet B; Felizarta F; Gutiérrez F; Pineda JA; Nichols G; Lou Y; Wire MB
Antimicrob Agents Chemother; 2009 Dec; 53(12):5185-96. PubMed ID: 19667283
[TBL] [Abstract][Full Text] [Related]
28. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
[TBL] [Abstract][Full Text] [Related]
29. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
[TBL] [Abstract][Full Text] [Related]
30. Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects.
Reddy YS; Ford SL; Anderson MT; Murray SC; Ng-Cashin J; Johnson MA
Antimicrob Agents Chemother; 2007 Apr; 51(4):1202-8. PubMed ID: 17261626
[TBL] [Abstract][Full Text] [Related]
31. Amprenavir.
Adkins JC; Faulds D
Drugs; 1998 Jun; 55(6):837-42; discussion 843-4. PubMed ID: 9617598
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
33. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Huang L; Wring SA; Woolley JL; Brouwer KR; Serabjit-Singh C; Polli JW
Drug Metab Dispos; 2001 May; 29(5):754-60. PubMed ID: 11302944
[TBL] [Abstract][Full Text] [Related]
34. Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.
Chaudry NI; Eron JJ; Naderer OJ; Pereira AS; Wire MB; Fiscus SA; Kashuba AD
Clin Infect Dis; 2002 Sep; 35(6):760-2. PubMed ID: 12203175
[TBL] [Abstract][Full Text] [Related]
35. A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.
Wood R; Eron J; Arasteh K; Teofilo E; Trepo C; Livrozet JM; Yeo J; Millard J; Wire MB; Naderer OJ
Clin Infect Dis; 2004 Aug; 39(4):591-4. PubMed ID: 15356829
[TBL] [Abstract][Full Text] [Related]
36. Amprenavir: new preparation. Another HIV protease inhibitor: no proven advance.
Prescrire Int; 2001 Jun; 10(53):70-2. PubMed ID: 11718166
[TBL] [Abstract][Full Text] [Related]
37. Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers.
Justesen US; Klitgaard NA; Brosen K; Pedersen C
J Antimicrob Chemother; 2004 Jul; 54(1):206-10. PubMed ID: 15150174
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers.
Brophy DF; Israel DS; Pastor A; Gillotin C; Chittick GE; Symonds WT; Lou Y; Sadler BM; Polk RE
Antimicrob Agents Chemother; 2000 Apr; 44(4):978-84. PubMed ID: 10722500
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection.
Grub S; Delora P; Lüdin E; Duff F; Fletcher CV; Brundage RC; Kline MW; Calles NR; Schwarzwald H; Jorga K
Clin Pharmacol Ther; 2002 Mar; 71(3):122-30. PubMed ID: 11907486
[TBL] [Abstract][Full Text] [Related]
40. Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults.
DiCenzo R; DiFrancesco R; Cruttenden K; Donnelly J; Schifitto G
Ann Pharmacother; 2009 Dec; 43(12):1972-7. PubMed ID: 19934383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
